GeneDx (NASDAQ:WGS – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at BTIG Research in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $85.00 target price on the stock. BTIG Research‘s target price points to a potential upside of 72.62% from the company’s previous close.
Several other research firms also recently weighed in on WGS. Canaccord Genuity Group lifted their target price on shares of GeneDx from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Wall Street Zen upgraded shares of GeneDx from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Guggenheim upped their price target on shares of GeneDx from $74.00 to $83.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Weiss Ratings reaffirmed a “sell (d)” rating on shares of GeneDx in a report on Monday, November 2nd. Finally, Zacks Research raised shares of GeneDx from a “hold” rating to a “strong-buy” rating in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $90.14.
View Our Latest Stock Analysis on GeneDx
GeneDx Stock Performance
GeneDx (NASDAQ:WGS – Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.07 by $0.21. The firm had revenue of $123.10 million for the quarter, compared to analysts’ expectations of $122.93 million. GeneDx had a positive return on equity of 1.98% and a negative net margin of 24.10%. During the same quarter in the prior year, the firm earned ($0.27) EPS. On average, analysts expect that GeneDx will post -0.37 earnings per share for the current year.
Insider Activity at GeneDx
In other news, CFO Kevin Feeley sold 3,728 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $97.61, for a total transaction of $363,890.08. Following the transaction, the chief financial officer directly owned 44,945 shares of the company’s stock, valued at approximately $4,387,081.45. This trade represents a 7.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Katherine Stueland sold 10,501 shares of the business’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $97.61, for a total value of $1,025,002.61. Following the completion of the sale, the chief executive officer directly owned 115,476 shares of the company’s stock, valued at approximately $11,271,612.36. This trade represents a 8.34% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 19,206 shares of company stock valued at $1,808,056. 25.17% of the stock is owned by insiders.
Hedge Funds Weigh In On GeneDx
Large investors have recently bought and sold shares of the stock. William Blair Investment Management LLC boosted its stake in shares of GeneDx by 11.4% during the third quarter. William Blair Investment Management LLC now owns 1,560,247 shares of the company’s stock valued at $112,806,000 after purchasing an additional 159,594 shares during the period. First Light Asset Management LLC grew its holdings in shares of GeneDx by 222.7% in the second quarter. First Light Asset Management LLC now owns 783,923 shares of the company’s stock worth $53,816,000 after purchasing an additional 540,996 shares during the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of GeneDx by 108.4% in the third quarter. Assenagon Asset Management S.A. now owns 632,413 shares of the company’s stock worth $45,723,000 after purchasing an additional 328,980 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of GeneDx by 2.0% in the second quarter. Wellington Management Group LLP now owns 347,927 shares of the company’s stock worth $23,885,000 after buying an additional 6,922 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in shares of GeneDx by 38.6% in the first quarter. Bank of New York Mellon Corp now owns 315,508 shares of the company’s stock worth $20,262,000 after buying an additional 87,922 shares during the period. 61.72% of the stock is owned by hedge funds and other institutional investors.
About GeneDx
GeneDx is a genomic testing company focused on helping clinicians diagnose rare and inherited conditions. Its services include whole exome and whole genome sequencing, along with other genetic tests and clinical interpretation of results. The company’s testing is used by healthcare providers to support diagnosis and care decisions, particularly for patients with suspected rare genetic disorders. GeneDx also offers testing related to hereditary cancer risk. Founded in 2000 by researchers with experience at the National Institutes of Health, GeneDx has developed its business around applying genomic information in clinical care.
Further Reading
- Five stocks we like better than GeneDx
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.
